Despite recent advances in cancer treatment, metastasis and therapy resistance remain among the major causes of cancer-related deaths worldwide. A recent pan-cancer study provides a comprehensive molecular profile of advanced and post-therapy tumors, integrating whole-genome and transcriptomic analysis with clinical outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.

References
Bailey, M. H. et al. Cell 174, 1034–1035 (2018).
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature 578, 82–93 (2020).
Pleasance, E. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-0050-6 (2020).
Robinson, D. R. et al. Nature 548, 297–303 (2017).
Zehir, A. et al. Nat. Med. 23, 703–713 (2017).
Priestley, P. et al. Nature 575, 210–216 (2019).
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Cell 168, 670–691 (2017).
Alexandrov, L. B. et al. Nature 578, 94–101 (2020).
Pich, O. et al. Nat. Genet. 51, 1732–1740 (2019).
Acknowledgements
E.R. is supported by funds from the Massachusetts General Hospital Cancer Center, The Breast Cancer Alliance, and the Broad Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests
Rights and permissions
About this article
Cite this article
Rheinbay, E. The genomic landscape of advanced cancer. Nat Cancer 1, 372–373 (2020). https://doi.org/10.1038/s43018-020-0057-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-0057-z